These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8452962)

  • 1. Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development.
    Czerkinsky C; Svennerholm AM; Holmgren J
    Clin Infect Dis; 1993 Mar; 16 Suppl 2():S106-16. PubMed ID: 8452962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunity: implications for vaccine development.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Immunobiology; 1992 Feb; 184(2-3):157-79. PubMed ID: 1587541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunity and vaccination.
    Holmgren J
    FEMS Microbiol Immunol; 1991 Dec; 4(1):1-9. PubMed ID: 1815705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholera as a model for research on mucosal immunity and development of oral vaccines.
    Holmgren J; Czerkinsky C
    Curr Opin Immunol; 1992 Aug; 4(4):387-91. PubMed ID: 1388838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.
    Levine MM; Kaper JB; Black RE; Clements ML
    Microbiol Rev; 1983 Dec; 47(4):510-50. PubMed ID: 6363898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory.
    Quiding M; Nordström I; Kilander A; Andersson G; Hanson LA; Holmgren J; Czerkinsky C
    J Clin Invest; 1991 Jul; 88(1):143-8. PubMed ID: 1905327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial enteric infections and vaccine development.
    Holmgren J; Svennerholm AM
    Gastroenterol Clin North Am; 1992 Jun; 21(2):283-302. PubMed ID: 1512046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of mucosal immune response following oral administration of enterotoxigenic Escherichia coli fimbriae (CFA/I) entrapped in liposomes in conjunction with inactivated whole-cell Vibrio cholerae vaccine.
    Dima VF; Ionescu MD; Palade R; Balotescu C; Becheanu G; Dima SV
    Roum Arch Microbiol Immunol; 2001; 60(1):27-54. PubMed ID: 11850896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of mucosal immunity in humans: relevance to vaccine development.
    Czerkinsky C; Holmgren J
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():37-44. PubMed ID: 7950860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery strategies to enhance oral vaccination against enteric infections.
    Davitt CJ; Lavelle EC
    Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel vaccination strategies for the control of mucosal infection.
    Husband AJ
    Vaccine; 1993; 11(2):107-12. PubMed ID: 8438609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal responses to parenteral and mucosal vaccines.
    Kaul D; Ogra PL
    Dev Biol Stand; 1998; 95():141-6. PubMed ID: 9855424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.
    Lycke N; Holmgren J
    Immunology; 1986 Oct; 59(2):301-8. PubMed ID: 3021614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunology of gut mucosal vaccines.
    Pasetti MF; Simon JK; Sztein MB; Levine MM
    Immunol Rev; 2011 Jan; 239(1):125-48. PubMed ID: 21198669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.
    Lebens M; Terrinoni M; Karlsson SL; Larena M; Gustafsson-Hedberg T; Källgård S; Nygren E; Holmgren J
    Vaccine; 2016 Apr; 34(18):2121-8. PubMed ID: 26973069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against enteric bacterial diseases.
    Hone D; Hackett J
    Rev Infect Dis; 1989; 11(6):853-77. PubMed ID: 2690285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.